Aspira Women's Health Provides Update on ARPA-H Sprint Program Partnership to Advance Women's Health
Aspira was originally awarded a $10 Million award through ARPA-H's Sprint for Women's Health to support the development of Aspira's ENDOinform test, a non-invasive blood draw-based multi-omics test utilizing protein and microRNA biomarkers, along with patient-specific data, to fuel a powerful, AI-powered algorithm to aid in the diagnosis of endometriosis in patients with symptoms of the disease.
This test, leveraging technology and expertise originally developed by Aspira for ovarian cancer risk assessment diagnostics, promises the potential to non-invasively confirm presence of suspected endometriosis in patients, enabling physicians to identify patients who may benefit from endometriosis-controlling therapeutics currently available.
The original ARPA-H contract was announced on October 24, 2024, and reflected $10 million divided into eight payments. The first two of those milestone payments, for $2 million and $1.5 million, were received on November 29, 2024, and March 28, 2025, respectively, for a total of $ 3.5 million from the ARPA-H program. On June 9, 2025, Aspira received notice from ARPA-H that ARPA-H and the assigned managing contractor, VentureWell, have determined that Aspira had not met the specifications of Milestone 3, and have therefore elected to terminate the ENDOinform development program contract.
Aspira's CEO, Mike Buhle, commented, 'While we are certainly disappointed in ARPA-H's termination notice, we are highly confident that our team fully achieved all specifications requirements in the Milestone 3 scope of work provisions. We achieved these requirements in early May and are well underway in achieving Milestone 4 targeted specifications. We are confident in our quality of work, and even more so in our understanding of the technical requirements to complete the ENDOinform program.'
Buhle further commented, 'Our R&D team has been excited about the progress we have made, as well as the early indications of our potential success with the ENDOinform program overall. We plan to continue development of this critical women's health program with the help and support of our shareholders, our research & collaboration partners, and the ongoing dedication of our highly talented and missional teammates. ENDOinform promises a dramatic improvement in health outcomes and quality of life for millions of women suffering from endometriosis, both in the U.S. and abroad. The program remains targeted for 2026 completion goals. We look forward to continuing our development work to completion. In fact, compliance with the ARPA-H program involved significant time investment for our R&D team, and this may well offer us a material acceleration in the pace of achieving our goals.'
About Aspira Women's Health Inc.
Aspira Women's Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases. OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuiteSM. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer risk for the 1.2+ million American women diagnosed with an adnexal mass each year.
OvaWatch provides a negative predictive value of 99% and is used to assess ovarian cancer risk for women where initial clinical assessment indicates the mass is indeterminate or benign, and thus surgery may be premature or unnecessary. Ova1Plus is a reflex process of two FDA-cleared tests, Ova1® and Overa®, to assess the risk of ovarian malignancy in women with an adnexal mass planned for surgery.
Our in-development test pipeline will expand our ovarian cancer portfolio and address the tremendous need for non-invasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, we intend to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our current tests. In endometriosis, we have developed the first-ever non-invasive test designed to identify endometriomas, one of the most commonly occurring forms of severe endometriosis. Through our ongoing endometriosis development program, we are combining microRNA and protein biomarkers with patient data, with the intent of identifying all endometriosis independent of disease location or severity.
Forward-Looking Statements
This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve a number of risks and uncertainties. Such forward-looking statements include statements regarding, among other things, the timing and completion of any products in the development pipeline and other statements that are predictive in nature, and whether the marketing of the OvaSuite portfolio will prove successful. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as 'designed to,' 'expect,' 'plan,' 'anticipate,' 'could,' 'may,' 'intend,' 'will,' 'continue,' 'future,' and other words of similar meaning and the use of future dates. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission (SEC), including those factors identified as 'Risk Factors' in our most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Aspira presently does not know, or that Aspira currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Aspira's expectations, plans, or forecasts of future events and views as of the date of this press release. Subsequent events and developments may cause the Company's assessments to change. However, while Aspira may elect to update these forward-looking statements at some point in the future, Aspira expressly disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Aspira's assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Investor Relations Contact:
[email protected]
SOURCE: Aspira Women's Health
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
2 minutes ago
- CBS News
Chinese research ship detected off Alaskan coast, Coast Guard says
A China-flagged research vessel was detected Friday off the coast of Alaska, the U.S. Coast Guard said. The Coast Guard reported Saturday that the Xue Long 2, an icebreaker, was detected about 290 nautical miles north of Utqiagvik, Alaska, in the U.S. Arctic. The Xue Long 2 is operated by China's Polar Research Institute. The ship was in the U.S.'s Extended Continental Shelf, or ECS, which is a portion of the continental shelf that goes beyond 200 miles nautical miles off the coast, according to the State Department. The ship was determined to be 130 nautical miles inside the ECS. "The U.S. has exclusive rights to conserve and manage the living and non-living resources of its ECS," the Coast Guard said in its news release. A Coast Guard C-130J Hercules, a long-range surveillance aircraft, responded to the ship. The Coast Guard also released a photo of the vessel. "The U.S. Coast Guard, alongside partners and other agencies, vigilantly monitors and responds to foreign government vessel activity in and near U.S. waters to secure territorial integrity and defend sovereign interests against malign state activity," said Rear Adm. Bob Little, commander of the U.S. Coast Guard Arctic District, in a statement. CBS News reached out the Coast Guard for clarification on how it was dealing with the vessel. Earlier this week, Canada's CBC News reported that the Canadian military was monitoring the movements of the Xue Long 2 in the Arctic. In a statement provided to the CBC Tuesday, Maj. Alexander Naraine, a spokesperson for the military's joint operations centre said that the Xue Long 2 was "not currently in Canadian territorial waters." Canada was using a Lockheed CP-140 Aurora aircraft based out of Alaska to "actively" monitor the Chinese ship, Naraine said. This comes after four Russian military planes were spotted and tracked flying near the Alaskan coast Tuesday by North American Aerospace Defense Command. The aircraft flew through a section of international airspace called the Alaskan Air Defense Identification Zone. While the Alaska ADIZ is considered part of international airspace, it is defined as an area where sovereign U.S. airspace ends but "that requires the ready identification of all aircraft in the interest of national security," according to NORAD. In January, American and Canadian fighter jets were scrambled after Russian warplanes were also spotted in the Arctic, NORAD said. The Russian warplanes remained in international airspace. And in July 2024, the U.S. intercepted several Chinese or Russian bombers near the Alaskan coast. At the time, a U.S. defense officials said it marked the first time ever that Russian and Chinese aircraft have jointly entered the Alaska ADIZ, and the first time Chinese H-6s have encroached off Watson, Emily Mae Czachor and Stephen Smith contributed to this report.
Forbes
2 minutes ago
- Forbes
Cancer Survivors: If You're A Hero, Why Are You Hiding It?
Love, bonding and woman with her mom with cancer hugging, sitting and spending time together. Happy, ... More sweet and sick mature female person embracing her adult daughter with a smile in outdoor garden. Cancer survivors have a great story to tell. They should tell it. I started this campaign 15 years ago – and here's the latest iteration. Over the last few weeks, I spoke with five interesting people who had five things in common. Here are the first four. They are all cancer survivors, they are all returning to the workplace after a long battle, they are all having a monumentally hard time getting a job, and they are all over 55. However, the fifth thing they have in common is why today's column came to be. They are all doing everything they can to hide these facts, especially the first one: the cancer. Now jump to thing five, the difficulty in finding a job. That's why I got their calls and emails. I gave them all the same advice. Tell people about it. Don't hide it. Get it out front and out of the way. This seemed counterintuitive to them – it may to you as well – and when I first laid it out, it made them uncomfortable. By the time we finished our conversations, though, they all agreed. And I'll bet many people reading this disagree initially, too. In fact, the advice these five people had gotten from everyone to whom they had previously spoken was opposite to mine – don't mention it, don't bring it up, don't discuss it, employers are not allowed to ask about that, if employers know they'll never hire you, it's none of their business, your previous employer is not allowed to mention it. And so on, ad infinitum. Well then, if that's the right advice, why are these people unable to find work? If they've hidden these facts, shouldn't that – based on those others' advice – lead to job opportunities? No, because it's bad advice. If you follow that line of strategic (?) thinking, and it goes month after month – in two cases, over a year – doesn't that indicate it might be faulty? This advice came from people who meant well: doctors, social workers, psychologists, religious leaders, people from the state department of labor, lawyers, family, friends, and so on. They just don't know the realities of the job market. In each case, we got around to how these five answered the 'what-have-you-been-doing-since-your-last-job?' and 'why-did-you-leave-your-last-job?' questions. OK, so how did they answer those questions? With every half-baked cockamamie answer you can think of, none of which holds water. Other than the truth, any answer is weak and suspect. If you think otherwise, go ahead; try any other answer and get back to me if you come up with one that sounds convincing – and that sounds like one that will move you to the second round of interviews. Now, one might think this is asking for trouble, that (as they all said) employers would not hire them due to fear they would get sick again and … you know the rest. Underneath it all, what's wrong with all this is that, in the eyes of many – me included – cancer survivors are heroes, and nothing less. They know all about the important things in life, like vision, determination, patience, goals, positive thinking, decision-making, responsibility, team work, bravery, and fortitude. Are these not the characteristics an employer looks for? So why hide this? Is it because you feel you'll get fewer calls or second interviews? Indeed you will, but that's OK. This deception game is the same faulty thinking that goes into the hide-my-age-by-leaving-stuff-off-my-resume fallacy. C'mon, some employers might be unfair to older workers or cancer survivors or anyone else, but they're not stupid. Whatever you try to hide will come out sooner or later. If you do the deceptive dance, they'll just find out later (not sooner), and then you'll just have wasted an awful lot of your time, not to mention keeping your hopes up artificially. So my suggestion is this. Start your cover letters off with a bold statement: 'After spending the last 10 months battling cancer, I have won that battle and am now re-entering the workplace.' Continue your letter as you would normally. You know what's going to happen? For sure, you will get fewer responses. But the ones you get are going to be real – very real. Don't you think there are people who admire what you've done? Don't you think a large number of hiring managers have either had the same experience you did or had a family member who did? Don't you think there are companies who are such avid supporters of cancer research that they sponsor 5K runs, Relay for Life, and other events in which we now all participate? The answers are yes, yes, and yes. And don't you think that, to these companies and managers, you're a hero? Yes again. Well then, let them know! The ones who will disqualify you because of what you've been through are jerks, and if by any slim chance you get this by them initially, what do you think will happen once this comes out? Jerks are always jerks; don't forget that. I'll take fewer calls any day of the week if they're sincere and real, wouldn't you? And if you can create the conditions under which that happens, why wouldn't you? Do not lose sight of one thing. You're a hero. And if you're a hero, why are you hiding it? P.S. I subsequently received letters of thanks from two different offices of the Aamerican Cancer Society, one of which published it in their newsletter. E.
Yahoo
30 minutes ago
- Yahoo
‘Star Trek: Starfleet Academy' Debuts Hopeful First Trailer With Holly Hunter and Paul Giamatti
'Star Trek: Starfleet Academy,' the newest series in the nearly 60-year-old franchise, warped into San Diego Comic-Con on Saturday with an introduction of its full cast and the first trailer for the show, which will debut in early 2026. The series takes place in the 32nd century after the events of 'Star Trek: Discovery,' with Starfleet relaunching the titular educational institution outside of San Francisco after the Federation's absence on Earth for more than 120 years. More from Variety 'American Dad' Producers on No Longer Getting to Swear as They Return to Fox; Upcoming Guest Stars Include RuPaul, Chris Pine 'The Simpsons' Upcoming Guests Include Kieran Culkin, Viola Davis, Idris Elba; Matt Groening on How to Liberate Parents from MAGA: 'Delete Fox News' 'Star Trek: Strange New Worlds' Teases Puppet Episode for Season 4 'We look at the generation now that is inheriting all of this division and all these major issues,' executive producer Alex Kurtzman said on the Hall H stage. 'We wanted to create a show that anchored us back to [Gene] Rodneyberry's essential vision of hope. How do you find it, how do you rebuild it?' Oscar-winner Holly Hunter plays Nahla Ake, the school's chancellor and the captain of the USS Athena; she greets the new class of cadets in the teaser, as it cuts to the cast exploring various parts of the campus. The teaser ends with a shot of Paul Giamatti as the season's main villain, Nus Braka, who is part-Klingon, part-Tellarite and is described in a Paramount release as 'a man with an ominous past connected to one of our cadets.' The main cadets on the show were revealed as: • Caleb Mir (Sandro Rosta), 'an orphan with a troubled past, and unlikely Starfleet cadet.'• Jay-Den Kraag (Karim Diané), 'a Klingon cadet who dreams of becoming a medical officer.'• Series Acclimation Mil (Kerrice Brooks), a.k.a. Sam, 'the first of her kind to ever attend Starfleet Academy.'• Darem Reymi (George Hawkins), 'an aspiring captain from a wealthy home world.'• Genesis Lythe (Bella Shepard),' an admiral's daughter determined to make her own name in Starfleet.' Other new characters include Tarima Sadal (Zoë Steiner), 'a Betazoid and daughter of the president of Betazed' and Commander Lura Thok (recurring guest star Gina Yashere), 'a Klingon/Jem'Hadar hybrid who is the chancellor's First Officer and Cadet Master.' Picardo is recurring his 'Star Trek: Voyager' character the Doctor, and Tig Notaro and Oded Fehr are reprising their 'Discovery' roles of Jett Reno and Admiral Vance, respectively. Best of Variety New Movies Out Now in Theaters: What to See This Week 'Harry Potter' TV Show Cast Guide: Who's Who in Hogwarts? Final Emmy Predictions: Talk Series and Scripted Variety - New Blood Looks to Tackle Late Night Staples
